TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company pioneering innovative therapies that target the tumor microenvironment (TME) in cancer treatment, has formally announced the convocation of its 2025 Annual General Meeting of Shareholders (AGM).
The AGM is scheduled to take place at 3:00 p.m. CEST on June 25, 2025, at the offices of Freshfields LLP, Strawinskylaan 10, Amsterdam, the Netherlands.
A key agenda item for the meeting is the Supervisory Board’s binding nomination of Diede Mink van den Ouden as the next Chief Executive Officer of TME Pharma N.V., subject to shareholder approval.
Van den Ouden, age 44, brings to the role a seasoned background in corporate investment and leadership. Since 2008, he has built a solid track record as a strategic investor in publicly listed companies, combining financial acumen with executive management experience. He currently serves as CEO and President of Tonner Drones SA, also listed on Euronext Growth Paris, and previously led a successful restructuring as CEO of Lavide Holding NV, where he orchestrated a key partnership with Haerlem Capital to secure the company’s future.
His engagement with TME Pharma includes a direct stake of 2,000,000 common shares, and, following a financing agreement announced on May 21, 2025, he is set to receive 4,980,000 warrants at an exercise price of €0.10 per share, further aligning his interests with the company’s long-term success.
The appointment marks a planned succession from current CEO Aram Mangasarian, who has led TME Pharma since 2015. Mangasarian will continue supporting the company as a strategic and scientific advisor, ensuring continuity in R&D oversight.
“Diede van den Ouden’s nomination reflects a strategic pivot toward reinforcing financial sustainability and unlocking shareholder value,” said Mangasarian. “His experience in public company governance and capital restructuring is critical to the next phase of TME Pharma’s growth. Moreover, his decision to accept a largely performance-based compensation package, alongside reduced remuneration for the Supervisory Board, demonstrates a strong commitment to fiscal discipline in line with the company’s evolving business model.”
The Supervisory Board expressed confidence that the proposed leadership transition will position TME Pharma to achieve its operational objectives and fortify investor confidence amid dynamic market conditions.
This year’s AGM will underscore TME Pharma’s continued commitment to transparent governance, stakeholder inclusivity, and disciplined financial management as it advances its clinical pipeline and long-term corporate strategy.
